Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eppalolitovolizumab plus chemotherapy as first-line versus second-line treatment for unresectable advanced or metastatic biliary tract cancer
ChiCTR2500102319Phase 4Not yet recruiting
- Sponsor
- Huaibei People's Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of eppalolitovolizumab in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer (2 arms), sponsored by Huaibei People's Hospital. Primary endpoint: Objective response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
eppalolitovolizumab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2500102319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102319.